Literature DB >> 29771765

Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus.

Sajan Jiv Singh Nagpal1, William R Bamlet2, Yogish C Kudva3, Suresh T Chari1.   

Abstract

OBJECTIVES: Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases.
METHODS: Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50).
RESULTS: Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM.
CONCLUSIONS: Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29771765      PMCID: PMC6139029          DOI: 10.1097/MPA.0000000000001077

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  21 in total

Review 1.  2. Classification and Diagnosis of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

Review 2.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

3.  Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.

Authors:  N Ueno; A Inui; M Iwamoto; T Kaga; A Asakawa; M Okita; M Fujimiya; Y Nakajima; Y Ohmoto; M Ohnaka; Y Nakaya; J I Miyazaki; M Kasuga
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

4.  Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus.

Authors:  Phil A Hart; Pratima Kamada; Kari G Rabe; Sunil Srinivasan; Ananda Basu; Gaurav Aggarwal; Suresh T Chari
Journal:  Pancreas       Date:  2011-07       Impact factor: 3.327

5.  Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction.

Authors:  Naureen Javeed; Gunisha Sagar; Shamit K Dutta; Thomas C Smyrk; Julie S Lau; Santanu Bhattacharya; Mark Truty; Gloria M Petersen; Randal J Kaufman; Suresh T Chari; Debabrata Mukhopadhyay
Journal:  Clin Cancer Res       Date:  2014-10-29       Impact factor: 12.531

6.  Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.

Authors:  Jan Škrha; Petr Bušek; Jana Uhrová; Petr Hrabal; Klára Kmochová; Martin Laclav; Bohuš Bunganič; Přemysl Frič
Journal:  Pancreatology       Date:  2016-12-15       Impact factor: 3.996

7.  Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.

Authors:  Gaurav Aggarwal; Vijaya Ramachandran; Naureen Javeed; Thiruvengadam Arumugam; Shamit Dutta; George G Klee; Eric W Klee; Thomas C Smyrk; William Bamlet; Jing Jing Han; Natalia B Rumie Vittar; Mariza de Andrade; Debabrata Mukhopadhyay; Gloria M Petersen; Martin E Fernandez-Zapico; Craig D Logsdon; Suresh T Chari
Journal:  Gastroenterology       Date:  2012-09-06       Impact factor: 22.682

Review 8.  Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?

Authors:  Nils Ewald; Reinhard G Bretzel
Journal:  Eur J Intern Med       Date:  2013-02-01       Impact factor: 4.487

9.  Beta-cell reserve capacity in chronic pancreatitis.

Authors:  S Domschke; K P Stock; J Pichl; M U Schneider; W Domschke
Journal:  Hepatogastroenterology       Date:  1985-02

Review 10.  Gut hormones and appetite control.

Authors:  S Hameed; W S Dhillo; S R Bloom
Journal:  Oral Dis       Date:  2008-10-17       Impact factor: 3.511

View more
  4 in total

1.  Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Authors:  Phil A Hart; Dana K Andersen; Kieren J Mather; Alicia C Castonguay; Mandeep Bajaj; Melena D Bellin; David Bradley; Noemy Contreras; Aida Habtezion; Murray Korc; Yogish Kudva; Maxim S Petrov; David C Whitcomb; Dhiraj Yadav; Ying Yuan; Jo Ann S Rinaudo; Sudhir Srivastava; Jose Serrano; Mark O Goodarzi
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

Review 2.  Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What's Known and What's to Know.

Authors:  Qiong Wei; Liang Qi; Hao Lin; Dechen Liu; Xiangyun Zhu; Yu Dai; Richard T Waldron; Aurelia Lugea; Mark O Goodarzi; Stephen J Pandol; Ling Li
Journal:  Front Physiol       Date:  2020-10-28       Impact factor: 4.566

Review 3.  Recent advances in understanding pancreatic cancer.

Authors:  Martyn C Stott; Lucy Oldfield; Jessica Hale; Eithne Costello; Christopher M Halloran
Journal:  Fac Rev       Date:  2022-04-20

Review 4.  Distinguishing diabetes secondary to pancreatic diseases from type 2 diabetes mellitus.

Authors:  Phil A Hart; Dana K Andersen; Maxim S Petrov; Mark O Goodarzi
Journal:  Curr Opin Gastroenterol       Date:  2021-09-01       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.